Alphabet Stock Gains Ahead of Google I/O; BofA Reaffirms Buy Rating
Technology Sarah Chen

Alphabet Stock Gains Ahead of Google I/O; BofA Reaffirms Buy Rating

Alphabet shares rose over 1% Monday, nearing $4.9 trillion market cap, as Bank of America reiterated Buy with $430 target ahead of Google I/O. Analysts highlight AI and cloud momentum but caution on elevated expectations.

GOOGL GOOG MSFT AMZN BKNG EXPE
Quince Therapeutics Faces Nasdaq Listing Uncertainty Amid Going Concern Warning
Markets Daniel Marsh

Quince Therapeutics Faces Nasdaq Listing Uncertainty Amid Going Concern Warning

Quince Therapeutics stock trades near $1.15 as the company faces Nasdaq compliance issues, a going concern warning, and a failed Phase 3 trial, with a shareholder vote on a reverse stock split scheduled for June 11.

QNCX
Berkshire Hathaway Takes Stake in Macy's; Stock Rises in Pre-Market
Markets Daniel Marsh

Berkshire Hathaway Takes Stake in Macy's; Stock Rises in Pre-Market

Berkshire Hathaway's new 3.04 million share stake in Macy's, valued at $55 million, lifted shares in pre-market. Q1 results are due June 3, with headwinds from tariffs and weak spending.

M BRK.B
ImmunityBio Secures Patents and BCG Supply Deal for Bladder Cancer Therapy
Technology Sarah Chen

ImmunityBio Secures Patents and BCG Supply Deal for Bladder Cancer Therapy

ImmunityBio announced five U.S. patents protecting its Anktiva-plus-BCG bladder cancer therapy through 2035, and an exclusive supply deal for the Tokyo-172 BCG strain.

IBIO
Markets Daniel Marsh

Virax Biolabs Surges on TV Segment and Ownership Filing

Virax Biolabs shares surged over 125% in pre-market trading Monday after a sponsored TV segment featuring its CEO and a new SEC filing revealed Armistice Capital holds a 4.99% stake.

VRAX
Hims & Hers Shares Slide on Convertible Note Sale, Dilution Worries
Markets Daniel Marsh

Hims & Hers Shares Slide on Convertible Note Sale, Dilution Worries

Hims & Hers Health shares declined 4% in pre-market trading after announcing a $300 million convertible note sale to finance its Eucalyptus acquisition and technology investments.

HIMS
Huachen AI Parking Surges 82% Premarket on Nasdaq Compliance Hopes
Markets Daniel Marsh

Huachen AI Parking Surges 82% Premarket on Nasdaq Compliance Hopes

Huachen AI Parking Management shares jumped 82% in premarket trading Monday, driven by Nasdaq compliance buzz and a recent reverse stock split. The stock reached $10.10 with volumes far above average.

HCAI
HIVE Digital Soars on C$3.5B AI Data Center Plan in Toronto
Technology Sarah Chen

HIVE Digital Soars on C$3.5B AI Data Center Plan in Toronto

HIVE Digital Technologies shares surged 33% in Nasdaq pre-market after its BUZZ HPC unit unveiled plans for a 320 MW AI infrastructure site near Toronto, with a C$3.5 billion investment target.

HIVE
T1 Energy Rises Premarket as Shareholder Vote on Capital Hike Nears
Markets Daniel Marsh

T1 Energy Rises Premarket as Shareholder Vote on Capital Hike Nears

T1 Energy Inc. stock traded up to $6.56 premarket Monday after closing at $5.67 Friday, as the company seeks shareholder approval to double authorized shares to 1 billion for its G2_Austin solar cell plant.

AI Data Center Boom Drives $66.8B NextEra-Dominion Merger
Markets Daniel Marsh

AI Data Center Boom Drives $66.8B NextEra-Dominion Merger

NextEra Energy is buying Dominion Energy for $66.8 billion in stock, forming the largest regulated electric utility globally to power AI data centers.

NEE D SO DUK
Bloom Energy Attracts Institutional Cash on AI Data Center Demand; Scalability Test Looms
Technology Sarah Chen

Bloom Energy Attracts Institutional Cash on AI Data Center Demand; Scalability Test Looms

World Investment Advisors and other institutions have taken stakes in Bloom Energy as the fuel-cell maker benefits from AI data center power demand. However, the company faces hurdles in scaling and execution.

BE ORCL PLUG FCEL BLDP AEP
GeoVax Shares Surge Pre-Market on Mpox Vaccine Trial Plans
Markets Daniel Marsh

GeoVax Shares Surge Pre-Market on Mpox Vaccine Trial Plans

GeoVax Labs shares surged pre-market Monday after announcing plans for a Phase 3 trial of its GEO-MVA mpox vaccine, though cash and funding risks remain key issues.

GOVX